Actively Recruiting
Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia
Led by Jemincare · Updated on 2025-02-03
50
Participants Needed
2
Research Sites
39 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A Phase 2a, Multicenter, Randomized, Open-label, Active Drug-controlled Trial to Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia
CONDITIONS
Official Title
Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to understand the procedures of this trial and provide written informed consent voluntarily
- Age 265 18 years, male or female
- On a stable hemodialysis regimen at a frequency of two or three times per week for at least 12 weeks prior to the screening visit
- Serum phosphorus within the trial-required range
You will not qualify if you...
- Any history of inflammatory bowel disease or diarrheal irritable bowel syndrome
- Pregnant or breastfeeding
- Any history of a parathyroid intervention
- Diarrhea or loose stools occurred within 1 week prior to randomization
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
Not Yet Recruiting
2
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
Actively Recruiting
Research Team
J
Jing Xu
CONTACT
W
Wei Chen
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here